BeiGene Overview
BeiGene (BGNE) has a ROE of 12.67%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow12.67%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BeiGene (BGNE) currently reports a ROE of 12.67%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore BeiGene's ROE history and peer comparisons.
BeiGene's ROE of 12.67% is higher than the Healthcare sector average of -100.59%. That is roughly 112.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BeiGene's current 12.67% should be judged against Healthcare norms (sector average: -100.59%) and against BGNE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 12.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for BeiGene, and consider following BGNE for alerts when major investors trade the stock.
BeiGene is classified in the Healthcare sector. On ROE, it currently shows 12.67% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BGNE with unrelated industries.
